NNIT A/S

DB:5NN Stock Report

Market Cap: €305.4m

NNIT Valuation

Is 5NN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5NN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 5NN (€11.96) is trading below our estimate of fair value (€38.85)

Significantly Below Fair Value: 5NN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5NN?

Key metric: As 5NN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 5NN. This is calculated by dividing 5NN's market cap by their current earnings.
What is 5NN's PE Ratio?
PE Ratio31.2x
EarningsDKK 73.00m
Market CapDKK 2.28b

Price to Earnings Ratio vs Peers

How does 5NN's PE Ratio compare to its peers?

The above table shows the PE ratio for 5NN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.3x
COP CompuGroup Medical SE KGaA
32.3x32.9%€812.2m
NXU Nexus
44.1x17.1%€1.2b
AJ91 DocCheck
16.9xn/a€41.4m
M3V MeVis Medical Solutions
7.7xn/a€44.4m
5NN NNIT
31.2x47.8%€2.3b

Price-To-Earnings vs Peers: 5NN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (25.3x).

Price to Earnings Ratio vs Industry

How does 5NN's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
5NN 31.2xIndustry Avg. 18.0xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 5NN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the European Healthcare Services industry average (18x).

Price to Earnings Ratio vs Fair Ratio

What is 5NN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5NN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.2x
Fair PE Ratio34.7x

Price-To-Earnings vs Fair Ratio: 5NN is good value based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5NN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€11.96
€16.42
+37.3%
14.3%€18.77€14.08n/a2
Nov ’25€13.72
€19.10
+39.2%
5.3%€20.10€18.09n/a2
Oct ’25€17.34
€19.10
+10.1%
5.3%€20.10€18.09n/a2
Sep ’25€13.92
€19.10
+37.2%
5.3%€20.11€18.10n/a2
Aug ’25€14.10
€18.43
+30.7%
1.8%€18.76€18.09n/a2
Jul ’25€14.20
€18.43
+29.8%
1.8%€18.77€18.10n/a2
Jun ’25€14.44
€18.44
+27.7%
1.8%€18.77€18.10n/a2
May ’25€14.18
€18.43
+30.0%
1.8%€18.77€18.10n/a2
Apr ’25€14.34
€14.08
-1.8%
33.3%€18.77€9.39n/a2
Mar ’25€14.00
€14.08
+0.6%
33.3%€18.78€9.39n/a2
Feb ’25€12.68
€12.74
+0.5%
26.3%€16.09€9.39n/a2
Jan ’25€11.14
€12.74
+14.4%
26.3%€16.09€9.39n/a2
Dec ’24€11.66
€12.74
+9.3%
26.3%€16.09€9.39n/a2
Nov ’24€10.76
€12.75
+18.5%
26.3%€16.10€9.39€13.722
Oct ’24€10.88
€12.75
+17.2%
26.3%€16.10€9.39€17.342
Sep ’24€10.68
€12.75
+19.4%
26.3%€16.10€9.39€13.922
Aug ’24€10.72
€12.75
+18.9%
26.3%€16.10€9.39€14.102
Jul ’24€10.30
€12.76
+23.8%
26.3%€16.11€9.40€14.202
Jun ’24€11.08
€12.76
+15.1%
26.3%€16.11€9.40€14.442
May ’24€9.53
€12.75
+33.8%
26.3%€16.10€9.39€14.182
Apr ’24€9.06
€12.75
+40.7%
26.3%€16.10€9.39€14.342
Mar ’24€9.47
€12.09
+27.6%
33.3%€16.12€8.06€14.002
Feb ’24€8.85
€12.10
+36.7%
33.3%€16.13€8.07€12.682
Jan ’24€8.50
€12.10
+42.4%
33.3%€16.14€8.07€11.142
Dec ’23€8.67
€12.09
+39.4%
33.3%€16.12€8.06€11.662
Nov ’23€7.19
€12.10
+68.3%
33.3%€16.13€8.07€10.762

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

1.0%

1Y

-34.2%

LNA Santé

€234.2m

Engages in the management and operation of health establishments.

2N3

€22.30

7D

-4.9%

1Y

16.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%